{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:15:12Z","timestamp":1760145312224,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.repc.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T02:21:09Z","timestamp":1699237269000},"page":"219-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one"],"prefix":"10.1016","volume":"43","author":[{"given":"Rodolfo P.","family":"Rothlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Facundo","family":"Pelorosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Nicolosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Fernandez Criado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Vetulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2023.08.005_bib0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.repc.2023.06.003","article-title":"Potential use of renin\u2013angiotensin\u2013aldosterone system inhibitors to reduce COVID-19 severity","volume":"42","author":"Gon\u00e7alves","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2023.08.005_bib0060","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.repc.2023.04.008","article-title":"RAAS inhibitors in COVID-19: they are not all the same!","volume":"42","author":"Kow","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2023.08.005_bib0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.repc.2023.06.003","article-title":"Reply to: RAAS inhibitors in COVID-19: not all are created equal!","volume":"42","author":"Gon\u00e7alves","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2023.08.005_bib0070","doi-asserted-by":"crossref","first-page":"e01083","DOI":"10.1002\/prp2.1083","article-title":"Telmisartan and losartan: the marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19","volume":"11","author":"Rothlin","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.repc.2023.08.005_bib0075","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial","volume":"18","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.repc.2023.08.005_bib0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"Stangier","year":"2000","journal-title":"J Int Med Res"},{"key":"10.1016\/j.repc.2023.08.005_bib0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"13","author":"Michel","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.repc.2023.08.005_bib0090","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/alz.12819","article-title":"Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans","volume":"19","author":"Zhang","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.repc.2023.08.005_bib0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cbf.3383","article-title":"Telmisartan protects against high glucose\/high lipid-induced apoptosis and insulin secretion by reducing the oxidative and ER stress","volume":"37","author":"Wang","year":"2019","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.repc.2023.08.005_bib0100","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2147\/DMSO.S265399","article-title":"Anti-diabetic effect of telmisartan through its partial PPAR\u03b3-agonistic activity","volume":"12","author":"Ayza","year":"2020","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255123004596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255123004596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:01Z","timestamp":1760109301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255123004596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0870255123004596"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2023.08.005","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.","name":"copyright","label":"Copyright"}]}}